Veracyte (NASDAQ:VCYT – Free Report) had its price objective trimmed by Stephens from $55.00 to $40.00 in a research note released on Wednesday,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.
A number of other analysts also recently issued reports on VCYT. Leerink Partners downgraded shares of Veracyte from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $55.00 to $35.00 in a report on Thursday, November 5th. Wolfe Research cut shares of Veracyte from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 6th. Weiss Ratings downgraded shares of Veracyte from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, September 24th. Zacks Research lowered Veracyte from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Finally, Morgan Stanley reduced their target price on Veracyte from $47.00 to $44.00 and set an “underweight” rating on the stock in a report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Veracyte has a consensus rating of “Hold” and an average target price of $44.50.
View Our Latest Stock Analysis on Veracyte
Veracyte Price Performance
Veracyte (NASDAQ:VCYT – Get Free Report) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.41 by $0.10. Veracyte had a net margin of 21.80% and a return on equity of 8.99%. The firm had revenue of $151.75 million for the quarter, compared to the consensus estimate of $147.13 million. During the same quarter in the previous year, the firm earned $0.51 earnings per share. The company’s quarterly revenue was up 15.1% compared to the same quarter last year. As a group, equities analysts expect that Veracyte will post 1.30 EPS for the current year.
Insider Buying and Selling at Veracyte
In other news, insider Phillip G. Febbo sold 13,110 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $43.05, for a total value of $564,385.50. Following the sale, the insider directly owned 133,048 shares in the company, valued at $5,727,716.40. The trade was a 8.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Karin Eastham sold 14,850 shares of the business’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $50.00, for a total transaction of $742,500.00. Following the completion of the sale, the director owned 10,247 shares in the company, valued at approximately $512,350. This trade represents a 59.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 62,609 shares of company stock valued at $2,858,904 over the last ninety days. Corporate insiders own 1.60% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in Veracyte during the second quarter worth approximately $792,058,000. Dimensional Fund Advisors LP increased its position in Veracyte by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,881,090 shares of the biotechnology company’s stock valued at $92,787,000 after acquiring an additional 80,614 shares during the last quarter. William Blair Investment Management LLC increased its position in Veracyte by 89.2% during the third quarter. William Blair Investment Management LLC now owns 2,709,212 shares of the biotechnology company’s stock valued at $124,732,000 after acquiring an additional 1,277,616 shares during the last quarter. GW&K Investment Management LLC increased its position in Veracyte by 70.1% during the third quarter. GW&K Investment Management LLC now owns 2,409,303 shares of the biotechnology company’s stock valued at $110,924,000 after acquiring an additional 992,760 shares during the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Veracyte by 64.9% in the first quarter. First Trust Advisors LP now owns 2,117,046 shares of the biotechnology company’s stock valued at $68,190,000 after acquiring an additional 833,543 shares during the period.
About Veracyte
Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.
Featured Articles
- Five stocks we like better than Veracyte
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
